Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662423 · ClinicalTrials.gov registry record · NA
Preventing Childbirth-Related PTSD With Expressive Writing
A NA study of PTSD (Childbirth-Related), sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT05662423: Recruiting NA study of PTSD (Childbirth-Related), sponsored by Massachusetts General Hospital.
NCT05662423 is a NA study of PTSD (Childbirth-Related) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 136 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05662423, a NA study of PTSD (Childbirth-Related), is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test a brief psychological intervention given to individuals in the first days following childbirth who have experienced a potentially stressful childbirth. The treatment is aimed at preventing post-traumatic stress disorder following childbirth and promoting maternal-infant bonding. In the days following childbirth, participants will be asked to write about their childbirth experience or a neutral event for three consecutive days, for around 15 minutes each day. Additionally, they will complete a short survey before and after the intervention about their birth experience and mental health. Around 2 months postpartum (with the option of up to around Month 3 PP), participants will take part in mental health and physiological assessments, and in a brief play session with their infant.
Primary Outcome
The PCL-5 is the standard self-report measure to assess PTSD symptom severity. It lists the 20 DSM-5 symptoms regarding a specified event (scale: 0-80, higher scores means worse outcome). In this study the event is specified to recent personal childbirth.
Conditions Studied
Interventions
- BEHAVIORAL Expressive Writing about Childbirth
- BEHAVIORAL Neutral Writing
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What NCT05662423 shows while recruiting
NCT05662423 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 1 condition, with PTSD (Childbirth-Related) appearing as the primary indexed condition, and to 2 interventions - of which Expressive Writing about Childbirth is the first listed.
NCT05662423 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05662423 about?
NCT05662423 is a clinical study titled "Preventing Childbirth-Related PTSD With Expressive Writing". The goal of this clinical trial is to test a brief psychological intervention given to individuals in the first days following childbirth who have experienced a potentially stressful childbirth. The treatment is aimed at preventing post-traumatic stress disorder following childbirth and promoting ma...
What is the current status of trial NCT05662423?
This trial is currently recruiting. It is a NA study. The enrollment target is 136 participants. The study started on 2023-11-08. Estimated completion is 2026-05-31.
What conditions does trial NCT05662423 study?
This clinical trial studies the following conditions: PTSD (Childbirth-Related).
What interventions are being tested in trial NCT05662423?
The interventions under investigation include: Expressive Writing about Childbirth (BEHAVIORAL), Neutral Writing (BEHAVIORAL).
Who is sponsoring clinical trial NCT05662423?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05662423 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD (Childbirth-Related)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05662423's enrollment target sits among peer trials
136 722nd of 2000 higher than 1,275 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI